Literature DB >> 12771950

Deletion mapping using quantitative real-time PCR identifies two distinct 3p21.3 regions affected in most cervical carcinomas.

Vera Senchenko1, Jian Liu, Eleonora Braga, Natalia Mazurenko, Witaly Loginov, Yury Seryogin, Igor Bazov, Alexei Protopopov, Fedor L Kisseljov, Vladimir Kashuba, Michael I Lerman, George Klein, Eugene R Zabarovsky.   

Abstract

We report chromosome 3p deletion mapping of 32 cervical carcinoma (CC) biopsies using 26 microsatellite markers located in frequently deleted 3p regions to detect loss of heterozygosity and homozygous loss. In addition, two STS markers (NLJ-003 and NL3-001) located in the 3p21.3 telomeric (3p21.3T) and 3p21.3 centromeric (3p21.3C) regions, respectively, were used for quantitative real-time PCR as TaqMan probes. We show that quantitative real-time PCR is reliable and sensitive and allows discriminating between 0, 1 and 2 marker copies per human genome. For the first time, frequent (five of 32 cases, i.e. 15.6%) homozygous deletions were demonstrated in CCs in both 3p21.3T and 3p21.3C regions. The smallest region homozygously deleted in 3p21.3C was located between D3S1568 (CACNA2D2 gene) and D3S4604 (SEMA3F gene) and contains 17 genes previously defined as lung cancer candidate Tumor suppressor genes (TSG(s)). The smallest region homozygously deleted in 3p21.3T was flanked by D3S1298 and NL1-024 (D3S4285), excluding DLEC1 and MYD88 as candidate TSGs involved in cervical carcinogenesis. Overall, this region contains five potential candidates, namely GOLGA4, APRG1, ITGA9, HYA22 and VILL, which need to be analysed. The data showed that aberrations of either NLJ-003 or NL3-001 were detected in 29 cases (90.6%) and most likely have a synergistic effect (P<0.01). The study also demonstrated that aberrations in 3p21.3 were complex and in addition to deletions, may involve gene amplification as well. The results strongly suggest that 3p21.3T and 3p21.3C regions harbor genes involved in the origin and/or development of CCs and imply that those genes might be multiple TSG(s).

Entities:  

Mesh:

Year:  2003        PMID: 12771950     DOI: 10.1038/sj.onc.1206429

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.

Authors:  Xun Zhang; Roger Gejman; Ali Mahta; Ying Zhong; Kimberley A Rice; Yunli Zhou; Pornsuk Cheunsuchon; David N Louis; Anne Klibanski
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

2.  Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Authors:  Joseph Kwong; Ji-Young Lee; Kwong-Kwok Wong; Xiaofeng Zhou; David T W Wong; Kwok-Wai Lo; William R Welch; Ross S Berkowitz; Samuel C Mok
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

3.  Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma.

Authors:  Nicola Potter; Aikaterini Karakoula; Kim P Phipps; William Harkness; Richard Hayward; Dominic N P Thompson; Thomas S Jacques; Brian Harding; David G T Thomas; Rodger W Palmer; Jeremy Rees; John Darling; Tracy J Warr
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

4.  Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer.

Authors:  Vera N Senchenko; Ekaterina A Anedchenko; Tatiana T Kondratieva; George S Krasnov; Alexei A Dmitriev; Veronika I Zabarovska; Tatiana V Pavlova; Vladimir I Kashuba; Michael I Lerman; Eugene R Zabarovsky
Journal:  BMC Cancer       Date:  2010-03-01       Impact factor: 4.430

5.  Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer.

Authors:  Vera N Senchenko; Natalia P Kisseljova; Tatyana A Ivanova; Alexey A Dmitriev; George S Krasnov; Anna V Kudryavtseva; Grigory V Panasenko; Evgeny B Tsitrin; Michael I Lerman; Fyodor L Kisseljov; Vladimir I Kashuba; Eugene R Zabarovsky
Journal:  Epigenetics       Date:  2013-03-11       Impact factor: 4.528

Review 6.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

7.  RBSP3 (HYA22) is a tumor suppressor gene implicated in major epithelial malignancies.

Authors:  Vladimir I Kashuba; Jingfeng Li; Fuli Wang; Vera N Senchenko; Alexey Protopopov; Alena Malyukova; Alexey S Kutsenko; Elena Kadyrova; Veronika I Zabarovska; Olga V Muravenko; Alexander V Zelenin; Lev L Kisselev; Igor Kuzmin; John D Minna; Gösta Winberg; Ingemar Ernberg; Eleonora Braga; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

8.  Assessment of the frequency of genetic alterations (LOH/MSI) in patients with intraepithelial cervical lesions with HPV infection: a pilot study.

Authors:  Monika Migdalska-Sęk; Agata Karowicz-Bilińska; Dorota Pastuszak-Lewandoska; Karolina H Czarnecka; Ewa Nawrot; Daria Domańska-Senderowska; Justyna Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-04-18       Impact factor: 3.064

9.  High mutability of the tumor suppressor genes RASSF1 and RBSP3 (CTDSPL) in cancer.

Authors:  Vladimir I Kashuba; Tatiana V Pavlova; Elvira V Grigorieva; Alexey Kutsenko; Surya Pavan Yenamandra; Jingfeng Li; Fuli Wang; Alexei I Protopopov; Veronika I Zabarovska; Vera Senchenko; Klas Haraldson; Tatiana Eshchenko; Julia Kobliakova; Olga Vorontsova; Igor Kuzmin; Eleonora Braga; Vladimir M Blinov; Lev L Kisselev; Yi-Xin Zeng; Ingemar Ernberg; Michael I Lerman; George Klein; Eugene R Zabarovsky
Journal:  PLoS One       Date:  2009-05-29       Impact factor: 3.240

10.  Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.

Authors:  Alla V Ivanova; Sergey V Ivanov; Ljudmila Prudkin; Daisuke Nonaka; Zhandong Liu; Anne Tsao; Ignacio Wistuba; Jack Roth; Harvey I Pass
Journal:  Mol Cancer       Date:  2009-10-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.